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 and middle-income settings. There is conflicting evidence on the potential
benefits of screening and treating these infections in pregnancy. Newly
available diagnostic technologies make it possible, for the first time, to conduct
definitive field trials to fill this knowledge gap. The primary aim of this study is to
evaluate whether antenatal point-of-care testing and immediate treatment of
these curable sexually transmitted and genital infections (STIs) leads to
reduction in preterm birth and low birth weight.
: The Women and Newborn Trial of Antenatal Interventions andMethods
Management (WANTAIM) is a cluster-randomised crossover trial in Papua New
Guinea to compare point-of-care STI testing and immediate treatment with
standard antenatal care (which includes the WHO-endorsed STI ‘syndromic’
management strategy based on clinical features alone without laboratory
confirmation). The unit of randomisation is a primary health care facility and its
catchment communities. The primary outcome is a composite measure of two
events: the proportion of women and their newborns in each trial arm, who
experience either preterm birth (delivery <37 completed weeks of gestation as
determined by ultrasound) and/or low birth weight (<2500 g measured within 72
hours of birth). The trial will also evaluate neonatal outcomes, as well as the
cost-effectiveness, acceptability and health system requirements of this
strategy, compared with standard care.
WANTAIM is the first randomised trial to evaluate theConclusions: 
effectiveness, cost-effectiveness, acceptability and health system requirements
of point-of-care STI testing and treatment to improve birth outcomes in
high-burden settings. If the intervention is proven to have an impact, the trial will
hasten access to these technologies and could improve maternal and neonatal
health in high-burden settings worldwide.
.Registration: ISRCTN37134032
Keywords
sexually transmitted infection, pregnancy, preterm birth, low birth weight,
cluster randomised crossover trial, Papua New Guinea
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Introduction
Background
Every year there are an estimated 2.6 million stillbirths and 
2.6 million neonatal deaths globally; the majority are in 
low- and middle-income countries (LMIC), primarily in remote 
and rural communities1. Papua New Guinea (PNG) has among the 
highest neonatal mortality ratios worldwide, with an estimated 
25 per 1000 live births in 2013, compared with a global figure 
of 182,3. Preterm birth and low birth weight are closely linked, 
as well as being independent and major contributors to neonatal 
mortality. Together, they affect around 20% of newborns in PNG4. 
The causes of preterm birth and low birth weight are diverse, 
but a range of infections including malaria, syphilis, and other 
sexually transmitted and genital infections (STI) have been 
implicated5–10. In many resource-limited countries, poor access 
to antenatal care means that opportunities for early diagnosis and 
clinical intervention of such infections are missed11.
Research studies among antenatal women in a number of LMIC 
have found extremely high rates of infection with genital STIs, 
particularly gonorrhoea, chlamydia, trichomonas and bacterial 
vaginosis, which are readily curable with cheap antibiotics5. In 
PNG, pregnant women have among the highest prevalence of 
these infections of any developing country12. In the country’s 
first bio-behavioural survey of STIs in pregnancy, we found that 
the prevalence of chlamydia was 23%, gonorrhoea 14%, and 
trichomonas 22%, with 44% of women having at least one of 
these infections13. Similar levels of infection were found in a 
pilot study of antenatal point-of-care STI testing and treatment 
conducted by our group14 in which 54% of women had one or 
more of chlamydia, gonorrhoea, trichomonas or BV, and the 
prevalence of each of these STIs was 19%, 11%, 38%, and 18%, 
respectively. Similar STI prevalences were also observed in an 
earlier randomised trial of malaria prevention in pregnancy15. 
In all of these studies, between 65–80% of infections among 
antenatal women were asymptomatic.
STIs and adverse birth outcomes
Gonorrhoea, chlamydia, trichomonas and bacterial vaginosis 
have been linked to adverse birth outcomes. The precise patho-
genesis remains unclear, with postulated mechanisms including 
direct infection of the foetus; stimulation of foetal inflammatory 
responses; excessive maternal immunogenic reactions; or a 
combination of factors16. There is evidence that gonorrhoea and 
chlamydia are associated with both preterm birth and low birth 
weight5,8,9,17–23, as well as miscarriage5,21, stillbirth5,24, premature 
rupture of membranes5,17,25, postpartum endometritis5 and oph-
thalmia neonatorum5. The reported strength of association 
varies across studies and endpoints8,26. In a meta-analysis, we 
found that trichomonas is associated with a relative risk of 
1.4 (95%CI: 1.1-1.7) for preterm birth27, and is also linked 
to low birth weight and premature rupture of membranes. 
Bacterial vaginosis is strongly associated with preterm birth and 
other adverse outcomes17,20,28. The population attributable risk 
of these infections as causes of adverse birth outcomes depends 
on their underlying population prevalence. For preterm birth, 
estimates have ranged from 15% for gonorrhoea, chlamydia, 
trichomonas and bacterial vaginosis individually, and up to 42% 
for a combination of one or more of these infections9,19,20.
Management of STIs in pregnancy
Diagnosis of genital infections has traditionally relied upon 
microscopy, culture, and/or serology, all of which require 
technical expertise and laboratory services which are not widely 
available in most resource-limited settings. Accordingly, in 
the 1990s, the World Health Organization (WHO) developed a 
syndromic management strategy for diagnosing genital infections 
that uses clinical presentation without laboratory confirmation 
to make treatment decisions. Syndromic management, however, 
cannot identify asymptomatic infections, which might contribute 
to its limited impact on disease prevalence12,29. The develop-
ment and introduction of nucleic acid amplification test (NAAT) 
technologies in the 1990s provided commercially available 
laboratory systems, which are highly accurate, robust for the 
detection of C. trachomatis, N. gonorrhoeae and T. vaginalis in 
both urine and genital swabs, and have relatively short turna-
round time. The costs and technical requirements of these 
platforms however have meant that they are not routinely available 
in resource-limited settings.
Following the successful implementation of point-of-care 
devices for the rapid diagnosis of syphilis and HIV, there was an 
effort to use similar strategies, generally based on lateral flow 
technology, for chlamydia, gonorrhoea and trichomonas 
testing, but the results were disappointing, largely due to poor 
sensitivity30–35. In the past 5 years, there has been a major 
breakthrough in rapid diagnosis of STIs. A fully automated 
portable NAAT platform (GeneXpert, Cepheid, Sunnyvale, 
CA) can perform tests for C. trachomatis, N. gonorrhoeae and 
T. vaginalis that are as accurate as laboratory-based NAATs. 
This platform has substantially improved the diagnosis and 
management of tuberculosis in many low- and middle-income set-
tings, including PNG36. Disposable cartridges hold the reagents 
including primers and probes for the simultaneous detection of 
chlamydia and gonorrhoea, with a separate cartridge used for 
trichomonas detection. Test results are available in approximately 
90 minutes for Xpert CT/NG and 60 minutes for the Xpert TV 
test. Building on the experience from the Test Treat ANd GO 
(TTANGO) Trial37 in remote Aboriginal communities in 
Australia, we showed the feasibility of point-of-care STI testing 
and treatment in a pilot study in selected antenatal settings in 
PNG37,38. The diagnosis of bacterial vaginosis has until recently 
relied on Amsel’s clinical criteria, or on highly skilled, time-
consuming microscopic examination of Gram stained vaginal 
smears using the Nugent score38–40. The BVBlue test (OSOM 
BVBlue Test, Gryphus Diagnostics, USA) is a chromogenic 
test based on the detection of increased vaginal fluid sialidase 
activity41. It is the first robust point-of-care test available for the 
diagnosis of bacterial vaginosis and, in previous evaluations, 
had high sensitivity (90%) and specificity (95%) compared with 
clinical and laboratory criteria41,42.
Significance and potential impact of the trial
Women in LMIC worldwide experience a high burden of adverse 
birth outcomes. The body of available scientific evidence about 
the effect of testing and treatment for STIs and other genital 
infections in pregnancy is conflicting. Recent reviews have 
concluded that there is insufficient evidence to inform policy on 
STI testing and treatment in pregnancy, and that field trials are 
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needed to confirm or refute earlier findings on the potential risks 
and benefits43–45. If we show a benefit for antenatal point-of-care 
STI testing and treatment, our findings could hasten access to 
these technologies and thereby lead to improved maternal and 
neonatal health. If no benefit is found, resources for maternal and 
neonatal health care can be directed elsewhere.
Protocol
Trial aim and objectives
The overall aim of the Women And Newborn Trial of Antenatal 
Interventions and Management (WANTAIM) is to measure 
the effectiveness, health system implementation requirements, 
cost-effectiveness and acceptability of antenatal point-of-care STI 
testing and immediate treatment to improve birth outcomes in 
high-burden, low-income settings. 
Primary Objective
1.    Evaluate whether point-of-care testing and immediate 
treatment of curable STIs in pregnancy leads to a reduction in 
preterm birth and/or low birth weight compared with standard 
antenatal care.
In this trial, ‘curable STIs’ includes C. trachomatis, N. gonorrhoeae, 
T. vaginalis and bacterial vaginosis, all of which will be tested 
for and treated at point-of-care in the intervention arm.
Secondary Objectives
1.    Evaluate whether point-of-care STI testing and treatment in 
pregnancy leads to an increase in mean birth weight compared 
with standard antenatal care;
2.    Evaluate whether point-of-care STI testing and treatment 
in pregnancy leads to a reduction in premature rupture of 
membranes compared with standard antenatal care;
3.    Evaluate whether point-of-care testing in pregnancy 
increases the diagnosis and treatment of STIs compared with 
symptom-based ‘syndromic’ management;
4.    Evaluate the cost-effectiveness of point-of-care STI testing and 
treatment in pregnancy compared with standard antenatal care;
5.    Evaluate the health system implementation requirements of 
point-of-care STI testing and treatment in pregnancy compared 
with standard antenatal care;
6.    Evaluate the acceptability of antenatal point-of-care STI 
testing and treatment compared with standard care;
7.    Evaluate whether point-of-care STI testing and treatment in 
pregnancy leads to a reduction in neonatal eye infection 
and/or pneumonia compared with standard antenatal care 
(among a sub-set of 2000 participants only);
8.    Evaluate mother-to-child transmission of C. trachomatis and 
N. gonorrhoeae (among a sub-set of 2000 participants only);
9.    Evaluate the performance of the XpertTM CT/NG Test for 
the diagnosis of neonatal eye infection and pneumonia using 
ocular and nasopharyngeal specimens (among a sub-set of 
2000 participants only).
Trial outcome measures
Primary
The primary outcome is a composite measure of two events, the 
proportion of women and their newborns in each trial arm who 
experience either:
a)    preterm birth (live birth before 37 weeks’ gestational age as 
estimated by ultrasound examination at 26 weeks’ gestational 
age or earlier, adjusted according to reported date of last 
menstrual period in accordance with trial standard operating 
procedures); and/or
b)    low birth weight (birth weight <2500 g measured as soon as 
possible after birth using calibrated, medical-grade infant 
weighing scales accurate to within 10 g; birth weights 
measured within 72 hours of birth only will be included in the 
primary outcome).
Secondary 
The trial secondary outcome measures are:
1.    Mean birth weight among newborns in the control and 
intervention arms of the trial;
2.    Proportion of women who experience premature rupture of 
membranes (defined as membrane rupture before the onset of 
labour);
3.    Number of curable STIs diagnosed and treated;
4.    Incremental cost effectiveness ratios (cost per preterm birth 
and/or low birth weight case averted; cost per STI diagnosed 
and treated; cost per life year saved; cost per disability-adjusted 
life year (DALY) averted);
5.    Health system implementation requirements;
6.    Acceptability of antenatal point-of-care STI testing and 
treatment among (a) women and (b) health workers.
7.    Proportion of newborns with an eye infection or moderate/
severe pneumonia by 4–6 weeks postnatal (among a sub-set of 
2000 participants only);
8.    Incidence of mother to child transmission of C. trachoma-
tis or N. gonorrhoeae as indicated by positive newborn eye 
(C. trachomatis or N. gonorrhoeae) or nasopharyngeal 
(C. trachomatis) swabs by 4–6 weeks postnatally (among a 
sub-set of 2000 participants only);
9.    Diagnostic test accuracy (sensitivity, specificity, positive and 
negative predictive values) of Xpert CT/NG Test compared 
with laboratory-based polymerase chain reaction (PCR) assays 
(among a sub-set of 2000 participants only).
The health economics research component of the trial will be 
described in detail in a separate protocol paper.
Trial design and setting
WANTAIM is a cluster-randomised controlled crossover trial46 
being conducted in 10 clusters in PNG. Trial clusters have been 
selected in consultation with provincial health authorities, church 
health services, health facility staff and other local stakeholders 
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using pre-defined criteria (e.g. antenatal attendance data, geo-
graphical location of health facility and catchment communi-
ties in relation to other potential trial clusters). A summary of 
trial interventions and visits in Figure 1 and a summary of trial 
procedures is provided in Figure 2.
Randomisation
The unit of randomisation is a primary health care facility and 
its catchment communities. Ten geographically distinct clusters 
will be assigned in a 1:1 ratio to control and intervention arms in 
the first phase of the trial. Following a washout period of 2-3 
months at the end of the first phase, each cluster will crossover 
to participate in the alternative trial arm in the second phase of 
the study (a so-called ‘A-B / B-A’ trial design). Randomisation 
will be stratified by province. In each province close to the 
start of recruitment, members of the local community advisory 
board, representatives from local health authorities, and staff 
from clinical research sites will be invited to a launch event in 
which the randomisation sequence will be selected by a senior 
independent stakeholder e.g. the Provincial Administrator. 
The Chief Investigator will prepare different randomisation 
sequences that will be put into separate identical opaque enve-
lopes. These will be placed in a traditional woven string bag 
(a bilum). The independent stakeholder will select one envelope 
from the bilum and open it to reveal the final sequence to the 
audience.
A subgroup of up to 2000 newborns will be followed up at 
1-2 weeks and 4–6 weeks postnatal to collect secondary outcome 
data (secondary objectives 7–9). Five of the 10 trial clusters 
will be randomly selected to participate in this part of the study. 
The randomisation sequence will be computer-generated and 
allocated by the trial statistician. Each of the clusters selected 
to participate in the extended postnatal follow-up component 
will do so during both the intervention and the control phase of 
the trial. Each selected cluster will thereby contribute around 
200 newborns in each trial phase (2000 in total).
Study participants and eligibility criteria
Women aged 16 years or over, attending antenatal clinic at 
26 weeks gestation or below (confirmed by obstetric ultrasound 
scan at first antenatal clinic visit), living within approximately 
one hour’s drive of a participating study clinic, and able to 
provide reliable contact details to facilitate future community 
tracing and postnatal follow-up, are eligible to join the study. 
Women found to be severely anaemic at enrolment (haemoglobin 
less than 6.0 g/dl accompanied by symptoms), or those with a 
permanent disability that prevents or impedes study participation 
Figure 1. Summary of trial interventions and visits.
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Figure 2. Summary of trial procedures.
and/or comprehension (such that it is not possible to obtain 
informed consent to participate), are excluded from participation 
in the trial. All those excluded on health grounds will be referred 
to the appropriate clinical specialist at each site, where they will be 
managed according to PNG national treatment guidelines47.
Recruitment and informed consent
Immediately prior to the start of enrolment at each site, potential 
participants will be notified that the trial is about to start through 
community meetings (e.g. at markets, after church), local media 
(e.g. broadcasts in PNG Pidgin [one of three official national 
languages in PNG], and local languages), and other mobilisation 
activities as advised by local stakeholders. Activities will be 
conducted by clinical research staff and members of the study 
community liaison team. On arrival at participating antenatal 
clinics, women will be provided with general information about 
the trial though a 5-10-minute group talk provided by a member 
of the clinical research team using a pictorial flipchart. Women 
who express an interest in taking part in the trial will be given a 
copy of the study Participant Information Sheet (available on 
Open Science Framework48) to read whilst waiting.
All participants will be required to complete written informed 
consent procedures prior to trial enrolment. All information 
and consent procedures will be conducted in PNG Pidgin or 
English, as preferred by the individual participant. In accord-
ance with ICH Good Clinical Practice guidelines (ICH GCP), 
participants unable to read and/or write will be required to have 
an impartial witness present during the above procedures.
Enrolment visit procedures
Women attending routine antenatal clinics in both the control and 
intervention arms of the trial will receive standard antenatal care 
in accordance with PNG national guidelines47. All women will be 
advised to return for a minimum of three additional antenatal clinic 
visits, in accordance with national and WHO recommendations; 
and to attend a health facility to give birth.
Procedures at enrolment: control clusters
a)    The following routine antenatal clinic procedures will be con-
ducted:47
○    A face-to-face clinical interview conducted in the most 
appropriate language (e.g. English or PNG Pidgin) to collect 
baseline antenatal data, including current and past obstetric 
history.
○    A general medical and obstetric examination, in which the fol-
lowing will be recorded: general health and well-being; signs 
of anaemia or other systemic disease (e.g. tuberculosis); weight 
and height; blood pressure; fundal height and foetal heart rate.
○    Provider initiated counselling and testing for HIV (PICT) and 
syphilis infection, as per PNG national guidelines.
○    Collection of specimens for routine on-site testing: haemoglobin 
(Hb) estimation; rapid diagnostic test (RDT) for malaria (if 
symptomatic e.g. fever); collection of a midstream urine speci-
men for urinalysis (protein and glucose testing).
○    Women will be provided with routine antenatal care as per PNG 
national guidelines, including sulphadoxine-pyrimethamine for 
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malaria prevention; iron and folate supplementation; tetanus 
toxoid immunization; treatment for syphilis if required; and 
STI syndromic management for women presenting with genital 
symptoms, as per PNG national guidelines.
○    Women with a positive RDT for malaria will be given 
malaria treatment in accordance with PNG national treatment 
guidelines.
○    Women who test positive for HIV infection will be referred 
for specialist review and initiation of antiretroviral therapy.
b) The following study-specific procedures will be conducted:
○    Collection of additional clinical, behavioural and socio- 
economic and demographic information, including risk 
factors for low birth weight and preterm birth (e.g. smoking, 
alcohol and betel nut consumption; recent or current systemic 
illness, e.g. malaria or tuberculosis; poor maternal nutritional 
status, e.g. mid-upper arm circumference <22 cm)49–51
○    A trans-abdominal obstetric ultrasound examination to 
measure biparietal diameter (BPD), head circumference (HC), 
femoral length (FL) and abdominal circumference (AC), to 
estimate gestational age, as specified in study-specific standard 
operating procedures.
○    Storage of residual urine specimen for off-site STI PCR 
testing to be conducted in batches in order to obtain infor-
mation on the prevalence of curable STIs (C. trachomatis, 
N. gonorrhoeae, T. vaginalis and bacterial vaginosis) among 
women participating in the control arm. Urine remaining 
after off-site STI testing will be retained for future laboratory 
testing with participants’ written consent.
○    Women with a positive urine test result will be counselled 
regarding their diagnosis and provided with treatment for 
them and their partner at the first postnatal visit conducted 
within 72 hours of birth.
○    A dried blood spot (DBS) will be collected and stored for 
later off-site malaria quantitative real-time PCR (qPCR) 
testing.
○    Information will be recorded in a study-specific Enrolment 
Case Report Form (CRF) at the time the measurements and 
interview are conducted.
○    A summary of key clinical findings will also be recorded in 
the participant’s Health Record Book that will be checked to 
see if any visits to a health centre have been documented. If 
the participant has any record of such a visit, the field study 
team will record the date of the most recent visit and any 
medication the participant received in the Enrolment CRF.
○    At the end of the Enrolment visit, a short interview with a 
dedicated community volunteer will be conducted in order 
to collect home address and other locator information to 
facilitate future community tracing and postnatal follow-up. A 
separate Locator Form will be used to record this information 
and will be securely stored in a different location to completed 
Enrolment CRFs.
Procedures at enrolment: intervention clusters
Enrolment procedures in intervention clusters will be identical 
to those in control clusters, with the following exceptions:
○    Women will provide two self-collected vaginal swabs for 
same-day, point-of-care testing at the study health centre:
a)    one swab will be tested for chlamydia, gonorrhoea and 
trichomonas using the GeneXpert platform; and
 b)   one swab will be tesed for bacterial vaginosis, using the 
BVBlue Test.
○    Clinic staff will use a laminated pictorial guide to help them 
explain the correct way to collect vaginal specimens for 
STI testing. During the explanation, staff will indicate how 
samples are to be collected using a specimen collection kit 
reserved for this purpose, and will encourage women to 
handle the swabs and to review the pictorial guide themselves.
○    When staff are satisfied that the participant understands the 
collection procedure, she will be asked to collect her 
specimens in a private room or the clinic toilet. This approach 
has been successfully used in our earlier research and 
found to be acceptable to both study participants and clinic 
staff.
○    Women who have a positive STI test result will be provided 
with immediate, directly observed treatment in accordance 
with PNG national guidelines for the management of STIs. 
Women will also be counselled regarding the importance of 
providing STI treatment for their husband/partner in order 
to prevent re-infection, and the most appropriate options 
for ensuring successful partner treatment (e.g. same-day 
treatment if accompanied by their partner; provision of a 
partner treatment pack; return for couple counselling and 
treatment).
○    Only those with a positive STI test result will be treated. 
STI syndromic management will only be provided for vul-
vovaginitis considered on clinical features due to candidiasis, 
for which additional treatment will be provided as per 
national guidelines (e.g. nystatin pessaries and/or clotrimazole 
cream)47.
○    If the test result on any of the above assays is invalid, women 
will be asked to provide an additional self-collected swab and 
given further counselling on self-collection, to allow repeat 
testing on the same day in the clinic.
○    Residual fluid remaining in the GeneXpert sample processing 
tube will be retained for future laboratory testing with partici-
pants’ written consent.
○    Urinalysis will be conducted as per routine antenatal care 
(e.g. for protein and glucose) but residual urine will not be 
stored in intervention clusters.
Procedures during antenatal follow-up
Following enrolment, women in both the control and intervention 
arms of the trial will receive standard routine antenatal care and 
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will be asked to re-attend for a minimum of three further antenatal 
clinic visits, in accordance with national guidelines:
1)    The first antenatal follow-up visit will be conducted 
approximately four weeks after trial enrolment;
2)    The second antenatal follow-up visit will be conducted 
approximately eight weeks after trial enrolment;
3)    The third antenatal follow-up visit will be conducted in the 
third trimester at approximately 34–36 weeks gestation.
Procedures during antenatal follow-up: control clusters
○    A general medical and obstetric examination, and conduct of 
routine antenatal investigations: haemoglobin estimation; RDT 
for malaria (if clinically indicated); collection of a midstream 
urine specimen for urinalysis (protein and glucose testing).
○    In addition to routine antenatal care, a short face-to-face 
interview will be conducted at all visits to obtain information 
on risk factors for low birth weight/preterm birth (e.g. smok-
ing, alcohol and betel nut use) and potential confounders 
(e.g. care-seeking, sexual behavioural data, condom use, 
concomitant antibiotic use for other non-genital infections).
○    Information will be recorded in study-specific CRFs at the 
time the measurements and interview are conducted.
○    Participants will be provided with health information at all 
visits, particularly the importance of having a supervised 
birth in a health facility, and reminded of the importance 
of informing the research team within 24 hours of giving 
birth if they have been unable to give birth at their local health 
facility.
○    All those who present with symptoms suggestive of a genital 
STI will be treated according to national syndromic manage-
ment guidelines.
○    At follow-up visits #1 and #3, a urine specimen will be 
collected and stored for off-site STI testing to be conducted 
in batches in order to obtain information on the prevalence of 
curable genital STIs among women participating in the control 
arm. Women who test positive for these infections (and their 
partners) will be provided appropriate treatment at their first 
postnatal visit.
Procedures during antenatal follow-up: intervention clusters
○    Follow-up procedures in intervention clusters will be identical 
to those in control clusters with the exception that at follow- 
up visits #1 and #3, women will be asked to provide two 
self-collected vaginal swabs that will be tested as per the 
enrolment visit. Women who have a positive STI test result 
provided with same-day treatment in the clinic.
Postnatal follow-up procedures
Women participating in the control arm of the trial who have a 
positive urine STI test result during antenatal follow-up will be 
provided with appropriate treatment by the study team at the 
first postnatal visit. Procedures for postnatal follow-up visits will 
otherwise be the same in each trial arm. Eye and nasopha-
ryngeal swabs will be collected from a sub-set of up to 2000 
newborns in five randomly selected trial clusters to address 
secondary objectives 7–9.
First postnatal follow-up visit (within 72 hours; all participants)
○    A first postnatal follow-up visit will be conducted by the trial 
team as soon as possible after birth to collect primary outcome 
data (birth weight, date and time of birth); and clinical informa-
tion, including adverse maternal and newborn health outcomes. 
Data will be recorded in study-specific CRFs at the time the 
measurements and interview are conducted. A summary of key 
findings will also be recorded in the participant’s client-held 
Health Record Book.
○    Participants who give birth at a health facility will be visited 
at the facility by a research nurse/midwife. Those who give 
birth in the community will be visited at home by a study 
community nurse/midwife.
○    The trial team will aim to conduct all first postnatal visits 
within 72 hours of birth. Baby weight measured in postnatal 
visits conducted more the 72 hours but less than 1 week after 
birth will be categorised as ‘late birth weight’ and will not 
contribute to the primary outcome.
○    Birth weight data recorded by labour ward staff in client-
held Health Record Books at the time of childbirth will be 
captured at postnatal visits conducted by the study team. If 
the study team have been unable to conduct a postnatal visit 
within 72 hours of birth, the birth weight as recorded in the 
client-held record book will be used in statistical analyses 
and contribute to the primary outcome of the trial. All health 
facilities participating in the trial (and other local facilities 
where study participants may give birth, such as provincial 
hospitals) will be provided with medical grade infant weigh-
ing scales accurate to within 10 g. Scales used by the study 
team and those at local health facilities will be calibrated 
monthly in accordance with study-specific standard operating 
procedures (SOPs).
○    Adverse maternal and/or neonatal health outcomes will be 
treated in the community and/or referred to local health 
services as indicated, in accordance with PNG national 
guidelines.
In clusters randomised to take part in the extended neona-
tal component of the trial, two eye swabs (one from each 
eye) will be collected from babies at this visit (for compari-
son of GeneXpert CT/NG Test and a laboratory-based NAAT 
platform)
Second postnatal visit (1–2 weeks; sub-set of 2000 participants 
only)
○    A second postnatal visit will be carried out in the partici-
pant’s home to collect information on adverse maternal 
and newborn health outcomes (including neonatal eye and 
respiratory symptoms) and health service utilisation.
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○    A neonatal examination will be conducted and baby weight 
measured as above. Adverse maternal and/or neonatal health 
outcomes will be treated in the community and/or referred 
to local health services as indicated, in accordance with 
PNG national guidelines.
○ The following specimens will be collected at this visit:
•    Two eye swabs from neonates with any clinical signs of 
conjunctivitis and from a random 15% sample of neonates 
with no clinical signs of conjunctivitis (one for GeneXpert 
CT/NG Test, and one for storage and later testing using a 
laboratory-based PCR platform)
•    Two nasopharyngeal swabs (one for Xpert CT/NG Test, and 
one for storage and later testing using a laboratory-based 
PCR platform)
○    Neonates with a positive test result will be followed-up in the 
community and provided with appropriate antibiotic treatment 
in accordance with PNG national guidelines.
○    Data collected during the visit (and any treatment provided 
and/or referral initiated) will be recorded in study-specific 
CRFs at the time of the visit. A summary of key findings will 
also be recorded in the participant’s Health Record Book.
Third postnatal visit (4–6 weeks; sub-set of 2000 participants 
only)
○    A third postnatal visit will be conducted home to collect 
information on adverse maternal and newborn health 
outcomes (including neonatal eye and respiratory symptoms) 
and health service utilisation. Visits will be conducted at 
participating health facilities when mothers and their 
babies attend for routine infant diphtheria-tetanus-polio 
(DTP) vaccination, or at home if participants miss a routine 
vaccination clinic.
○    Data will be extracted from client-held health record books 
and health facility records of investigations, diagnoses and 
treatment where available.
○    Procedures for the collection of health information, and 
treatment provided will be the same as at the second postnatal 
visit, described above.
○    The following specimens will be collected at this visit:
•    Two nasopharyngeal swabs (one for Xpert CT/NG Test, and 
one for storage and later testing using a laboratory-based 
PCR platform).
•    Eye swabs will not be collected unless clinically indicated 
at this visit.
○    Infants with a positive test result will be followed-up in the 
community and provided with appropriate antibiotic treatment 
in accordance with PNG national guidelines.
Collection of economic evaluation data
The cost effectiveness analysis will be performed according to 
the intention-to-treat principle and from a health service and 
societal perspective. It will measure and value the resource 
use of providers and participants. This includes all costs of the 
intervention, including local health service implementation net 
costs (such as the costs of service provision, medicines, diagnos-
tic tests, changes to staff time, other aspects of workflow, and 
supervision, adjusting for any user fees observed); participant 
out-of-pocket costs (such as transport, accommodation); and 
costs of production losses (such as participant’s and family’s 
time-off work or normal activities). The project costs of delivering 
the intervention will be collected retrospectively from the project 
accounts and entered into a standardised data capture tool designed 
for this purpose following standard practice52. Costs incurred by 
health care providers (i.e. participating health facilities) will be 
collected prospectively from health service records (below) that 
capture data on changes in service provision, patient flow, staff 
allocation of time, and resource use (drugs and equipment); 
combined with available financial data on the average unit cost 
of delivering the services in both arms of the trial53. Participant 
costs will be assessed prospectively using a context-specific 
client CRF covering cost of care-seeking that will be adminis-
tered by research staff to all participants at enrolment, at antena-
tal follow-up visits and postnatally. This CRF will also include 
questions to assess client acceptability of the intervention 
(see below). The health economics research component of the trial 
will be described in detail in a separate protocol paper.
Collection of health system implementation data
All trial facilities will be assessed at baseline and up to twice 
during implementation to collect health service data through 
examination of facility records, observation of facility proce-
dures, and semi-structured interviews (SSIs). SSIs will collect 
provider costs (capital and recurrent) and other health service 
feasibility and acceptability data, including changes in service 
provision, patient flow, staff allocation of time, and resource use 
(drugs and equipment). SSIs will be conducted with members 
of the in-country clinical research team (1–3 staff per cluster; 
10–30 interviews in total); clinic staff in participating antena-
tal clinics (1–3 staff per facility; 10–30 interviews in total); and 
health managers at district, provincial, national level (10–15 
interviews in total). Health care managers and providers being 
interviewed or observed will complete separate informed consent 
procedures, and interviews digitally recorded with participants’ 
consent. Interview topics will include:
○    Rapid health system screen for changes in antenatal service 
delivery, facility staffing, health information, financing 
and payments, clinical governance, and community/patient 
engagement.
○    Staff workflow and patient flow specific to the conduct of 
point-of-care STI testing, counselling and treatment.
○    Provider views on training requirements, confidence in 
test results obtained, experiences of providing results to 
participants.
○    Provider views on resources needed in terms of capital and 
recurrent costs to health service and clients, staffing and 
infrastructure.
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○    Provider views on changes in client attitudes to and utilization 
of antenatal services, including frequency and timeliness.
○    Opinions on enablers of and barriers to deployment of 
antenatal point-of-care STI testing in general and GeneXpert-
based point-of-care testing in particular.
An observational assessment and an examination of facility 
records will also be conducted at the time facilities are visited 
for SSIs. The observational assessment comprises a structured 
observation of clinic processes, and will include quantification 
of staff work-flow and patient-flow. Observational assessments 
will be conducted at baseline, and at early and late time points 
during trial implementation at clinical sites. The examination of 
facility records will review clinic activity levels relevant to the 
study including staff time and other resource allocations, utilisa-
tion patterns, timeliness of antenatal care, clinical complications 
of pregnancy and timing of diagnosis and treatment.
Collection of acceptability data
Client acceptability of the intervention, and accompanying 
service changes, will be measured in two ways. First, questions 
embedded in the CRF on cost of care-seeking (see above) will 
be administered by research staff to all participants at enrolment, 
and antenatal and postnatal follow-up visits. These data will be 
supplemented by SSIs (coordinated with the SSIs conducted 
above) in a subset of up to 200 women, enabling qualitative 
triangulation of issues raised in other data collection activities. 
Interviews will be administered by research staff trained in 
culturally sensitive collection of qualitative information. Due 
to the iterative, validating role of these SSIs, their structure 
and themes will be revised (within the confines of the outline 
interview guide approved by research ethics committees) 
based on early findings from acceptability CRFs and provider 
interviews.
Adverse events and safety reporting
Reporting framework. Adverse Events (AEs) occurring during 
the course of the trial will be monitored, managed and reported 
in accordance with guidance from the UK Medical Research 
Council, and the UK National Health Service Health Research 
Authority, in particular their guidance on safety reporting in 
human research trials that are not clinical trials involving inves-
tigational medicinal products (non-CTIMP trials: https://www.
hra.nhs.uk/approvals-amendments/managing-your-approval/
safety-reporting/). The WANTAIM trial is evaluating the use 
of established STI diagnostic assays and providing the same 
antibiotics for the treatment of infections as currently used for 
STI syndromic management in PNG. No new investigational 
medicinal products are being evaluated in the trial.
Protocol definition of Serious Adverse Event. The protocol 
definition of a serious adverse event (SAE) is based on UK 
guidance for non-CTIMPs trials (Box 1). This definition is 
consistent with ICH GCP and current MRC UK guidelines. All 
SAEs as defined will be reported within 72 hours of the Trial 
Coordinator and/or Chief Investigator becoming aware of the 
event.
Box 1. Protocol definition of serious adverse event.
In research other than CTIMPs, a serious adverse event 
(SAE) is defined as an untoward occurrence that:
(a) results in death;
(b) is life-threatening;
(c) requires hospitalisation or prolongation of existing 
hospitalisation;
(d) results in persistent or significant disability or incapacity;
(e) consists of a congenital anomaly or birth defect; or
(f) is otherwise considered medically significant by the 
investigator.**
An SAE occurring to a research participant should be 
reported to the main Research Ethics Committee where in 
the opinion of the Chief Investigator (CI) the event was:
•    Related – that is, it resulted from administration of any of the 
research procedures, and
•    Unexpected – that is, the type of event is not listed in the 
protocol as an expected occurrence.
** In the WANTAIM trial, the following conditions will be 
considered medically significant and categorized as SAEs:
•    spontaneous abortion / miscarriage
•    stillbirth
•    early neonatal death
•    domestic violence resulting in injury that requires medical 
attention
Sample size
Sample size requirements were based on our earlier findings 
about the incidence of the primary outcome in PNG13–15,54. The 
proportions of pregnancy resulting in preterm birth and low birth 
weight were estimated to be 15% each, and 18% combined. 
Research findings on the relationship between STIs and birth 
outcomes suggest that effective STI treatment could reduce this 
combined proportion by up to 45%27,55 in those with STIs. This 
reduction would translate into a relative reduction of around 
23% in a population in which nearly half of all pregnant women 
have chlamydia, gonorrhoea, trichomonas and/or bacterial 
vaginosis, as is the case in PNG14. To measure this effect size 
with α=0.05, β=0.20 (80% power), and an estimated intra-cluster 
correlation coefficient (ICC) of 0.003, 16 clusters of 200 women 
would be required in a cluster randomised crossover trial 
(8 clusters per phase; 3200 women in total). In case one or more 
trial cluster does not successfully complete the trial, two additional 
clusters will be added (10 clusters of 200 women in each 
phase; 4000 women in total). Based on our earlier work in this 
setting54,56,57, we anticipate loss to follow-up for the primary 
outcome of around 10–15%, so we will recruit a total of 4600 
women from 10 clusters in two phases (230 women per cluster 
in each phase of the trial).
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Methods for minimising bias
To minimise the risk of selection bias due to differences in the 
proportion of eligible women enrolled in larger compared to 
smaller clinical centres:
○    Human resource allocation, equipment, consumables and 
logistics support will be increased in clusters having the 
highest weekly attendance figures to facilitate optimal 
participant accrual across all sites.
○    Site-level accrual will be monitored weekly by the Trial 
Coordinator and presented at quarterly Trial Management 
Group (TMG) meetings held throughout the course of the 
trial. The total number of women attending their first 
antenatal clinic visit, total enrolled, total excluded, and total 
who declined to join the study, will be recorded in a weekly 
tally sheet at each site.
Attrition bias in the ascertainment of outcomes will be minimised 
by the use of previously tested strategies for ensuring high levels 
of follow up. To minimise performance bias we will be using the 
same procedures for routine antenatal care in all clinics. Detection 
bias will be minimised by assessing outcomes as objectively as 
possible and by blinding assessments wherever possible.
Statistical analysis
The statistical analysis plan for the trial will be presented in 
detail in a separate manuscript.
All analyses (including the cost-effectiveness analysis) will be 
conducted using methods that take into account the cluster- 
randomised cross-over design. All analyses will be carried out 
using the latest available version of Stata statistical software 
(15.0 or above; College Station, TX, USA).
Primary data analysis will be by intention to treat (ITT) at the 
cluster level, meaning that all participants with a recorded 
outcome will be included in the analysis, and will be ana-
lysed according to the treatment group to which they were 
randomised; and all clusters will be included in the analysis 
according to the treatment group to which they were randomised. 
Initial analyses will be unadjusted comparisons of interven-
tion and control clusters. If there appear to be any important 
imbalances between randomised groups in terms of baseline 
demographic characteristics, risk factors for low birth weight 
and/or preterm birth, and the prevalence of specific STIs, 
adjusted analyses will be performed, and presented in addition to 
unadjusted comparisons.
Effect measures, comparing outcomes between intervention 
and control clusters, will be estimated with 95% confidence 
intervals and p-values from the corresponding hypothesis 
tests. The effect measure for the primary outcome will be a risk 
ratio, defined as the ratio between the proportion recorded as 
having the outcome of interest in the intervention arm, and the 
corresponding proportion in the control arm.
Data management
Data will be collected using paper-based CRFs at each visit 
(enrolment, antenatal follow-up and postnatal visits). All CRFs 
will be designed in TeleForm Elite version 10.5 and uploaded 
into a secure centrally located clinical trials database created in 
ORACLE. Completed CRFs will be checked on the day of 
completion and any errors, discrepancies or out of range values 
will be corrected by study staff. Any corrections or alterations 
to the original CRF will be initialled by the member of staff. 
Original copies of the CRF will be held at the clinic in a locked 
filing cabinet accessible only by the clinic staff and the dedicated 
trial Data Manager. For the purposes of ICH GCP, completed 
CRFs will be considered source documents. Completed CRFs 
will be electronically scanned, either at the clinic or at a central 
facility, on a weekly basis (e.g. the day following new antena-
tal enrolments) using a portable scanner into a computer using 
a tagged image file format (TIFF). Data will be stored in a 
dedicated electronic folder prior to verification using TeleForm. 
A copy of the locally-held data will then be uploaded using 
TeleForm into a dedicated study-specific ORACLE database 
located on a secure, off-site server at UNSW Sydney, Australia. 
ORACLE is compliant with ICH GCP E6 and with United States 
Food and Drugs Authority (FDA) guidance58 (Title 21 of the Code 
of Federal Regulations (CFR) Part 11;Available at: http://www.fda.
gov/RegulatoryInformation/Guidances/ucm125067.htm). UNSW 
Sydney will provide IT and technical support to the study team for 
the duration of the trial.
Following successful data upload, locally held data (TIFF 
scans) will be moved to a dedicated folder indicating completed 
data entry. Data entry and review will be ongoing activities dur-
ing the entire trial period and will be conducted in accordance 
with study-specific SOPs. A random sub-set of electronic records 
from the master data base will be checked for accuracy against 
the scanned electronic TIFF files of participant CRFs every 
three months by the in-country trial Data Manager and Trial 
Coordinator. Electronic versions of the locked datasets and TIFF 
files for this study will be maintained as part of the PNG Insti-
tute of Medical Research (PNGIMR) research studies database. 
Electronic STI test results will be uploaded monthly into the 
ORACLE database as per study-specific SOPs, using a program 
developed at UNSW that enables test data to be extracted by 
Study ID Number from the .GXX data files generated by the 
GeneXpert platform. Electronic data held on portable ultrasound 
machines will also be regularly extracted for off-site back-up, as 
per study-specific SOPs.
The electronic trial database will be backed up both onsite (at 
PNGIMR) and off-site (at UNSW Sydney) at regular intervals 
as specified in study-specific data management SOPs. Copies of 
the databases generated in PNG and interim datasets will also be 
sent to the study CIs at regular intervals. At the end of the trial, 
the database will be locked following final data entry and database 
cleaning, and will then be provided to the Trial Statistician for 
data analyses. After completion of data analyses, copies of the 
final database and analytical datasets (neither of which will 
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contain any subject identifying information) will be maintained 
on secure servers located at the PNGIMR and UNSW Sydney.
Ethical considerations
Confidentiality
Participant confidentiality will be maintained throughout the 
trial. All participants will be allocated a unique alphanumeric trial 
identification (ID) number that will be used to identify clinical 
and laboratory information in paper-based and electronic records 
to ensure confidentiality. Participants will not be identified by 
name. Names and identifier information will be recorded in the 
trial enrolment log (used to allocate trial ID numbers) and in 
study informed consent forms. These will be securely stored 
in a separate location to that used to store completed CRFs and 
laboratory records. Data uploaded to the centralised ORACLE 
clinical trials database will be identified only by trial ID number 
and participant initials.
Informed consent
Women will be provided with general information about the trial 
on arrival at participating antenatal clinics though a 5-10 minute 
group talk provided by a member of the clinical research team. 
A pictorial informed consent flipchart will be used to supple-
ment the talk and to explain key topics in more detail. The 
research team will not disclose information on whether the clinic 
is currently participating in the intervention or control arm of 
the trial. At the end of the talk, copies of the study participant 
information sheet will be provided to participants. Women who 
are interested to join the study will be assessed for eligibil-
ity by a member of the research team prior to formal informed 
consent procedures. Women who choose not to participate in 
the study or are ineligible will be assured of receiving standard 
care in full accordance with PNG standard treatment guidelines. 
Women will then be asked to complete formal written informed 
consent procedures that will include a short comprehension 
checklist completed by study staff to confirm that each partici-
pant understands key aspects of the trial prior to enrolment. In 
accordance with ICH GCP, participants who are unable to read 
and/or write will be required to have an impartial witness present 
during consent procedures. Example flipcharts in English and 
Pidgin, alongside informed consent forms, are available on Open 
Science Framework48.
Ethical approval
The trial protocol has been approved by the Institutional Review 
Board of the PNG Institute of Medical Research (IRB number 
1608); the Medical Research Advisory Committee of the PNG 
National Department of Health (MRAC number 16.24); the 
Human Research Ethics Committee of the University of New 
South Wales (HREC number 16708); and the Research Ethics 
Committee of the London School of Hygiene and Tropical 
Medicine (REC number 12009).
SPIRIT checklist
 A SPIRIT checklist for the trial protocol is available from Open 
Science Framework48.
Trial governance and oversight
Trial Steering Committee (TSC)
Primary responsibility for the conduct of the trial will rest with 
this committee that will be constituted according to MRC and 
ICH GCP guidelines59–61. Approved terms of reference for the 
TSC will be made available via the trial website. The TSC 
will meet prior to the start of the trial and then approximately 
twice a year to review progress, eligibility issues, adverse birth 
outcomes, and to consider any recommendations from the 
Data and Safety Monitoring Board (DSMB). The trial may be 
terminated by the TSC for any reason, including a recommen-
dation of the DSMB. The TSC will be responsible for approv-
ing the trial protocol prior to its submission for national and 
international ethics committee review. Any protocol amendments 
or sub-studies to the main trial will also be submitted to the TSC 
for consideration prior to ethics approval. The TSC will also 
approve the trial monitoring plan and the statistical analysis plan 
prior to the start of participant enrolment; and be responsible for 
approving abstracts, conference presentations and manuscripts 
prior to their submission.
DSMB
The DSMB will oversee the trial and be comprised of senior 
researchers in maternal and child health, trial statisticians and 
provincial and national policy makers working in maternal 
health in PNG. The DSMB will provide expert advice and 
guidance to the TSC and will review primary trial outcome data 
every 4–6 months, including the possibility that point-of-care 
STI testing and treatment may be enhancing rather than reducing 
adverse birth outcomes. The DSMB will also review all SAE 
Reports. The DSMB will review incidence rates in the differ-
ent study arms and advise the TSC on any revision of the sample 
size required during the course of the trial. Meetings will be 
coordinated by the Chief Investigator, and the Trial Statistician 
will supervise and prepare the tables in the format approved by 
the DSMB.
TMG
The day-to-day management of the trial will be overseen by 
the TMG, which will meet on a regular basis (every 2–4 weeks 
at the start of the trial and then quarterly) to review progress, 
including accrual and retention; eligibility and exclusions; STI 
diagnoses and treatment; data management issues; and logisti-
cal considerations. The TMG will also ensure that the routine 
operations of the trial proceed in accordance with the trial proto-
col and study-specific SOPs, and will engage with stakeholders 
and participating communities on an ongoing basis to provide 
progress updates on the conduct of the trial. TMG meetings 
will be coordinated by the Trial Coordinator and chaired by the 
Chief Investigator (CI).
Trial monitoring
The trial will be independently monitored in accordance with 
MRC guidance and ICH GCP. As per ICH GCP E6, section 
5.18.1, the purpose of trial monitoring will be to verify that: the 
rights and well-being of human subjects are protected; reported 
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trial data are accurate, complete, and verifiable from source 
documents; and the conduct of the trial is in compliance with 
the approved protocol/amendment(s), with ICH GCP, and with 
applicable regulatory requirements. The Trial Monitor will have 
experience in monitoring large-scale clinical trials in similar 
settings to the current study and will be familiar with the trial 
protocol, relevant ethical and regulatory requirements, and 
study-specific SOPs. Prior to the start of the study, trial inves-
tigators will prepare a Monitoring Plan for endorsement by 
the TSC and the Trial Sponsor that will provide a framework 
for routine monitoring during the trial. This document will 
be based on UK MRC guidance61 and indicate the extent 
(e.g. scope, detail, depth), timing, and reporting arrangements to 
be followed. 
Data sharing and access
A study-specific website will be established and have a linked 
web-based data repository, enabling data reuse and sharing. 
Access will be provided using web-based tools and applications. 
We will provide all necessary information including a descrip-
tion of the data repository system, and unique identifiers to 
allow it to be cited correctly. The study team will also make 
datasets available via the Open Science Framework and/or the 
Australian Research Data Common portal. Potential users can 
discover our data through these web-based resources and via 
open access publications and international conference presenta-
tions. Access to databases, survey tools, training materials and 
software tools developed by the study team will only be available 
for non-profit purposes. Consistent with MRC data sharing guide-
lines, our data management policy will outline the governance of 
access to research data. The TSC will have overall responsibility 
in deciding what categories of new users are able to access dif-
ferent types of information at different time points during and 
after completion of the trial, and will review applications by 
new users to undertake additional analyses using trial data.
The study team will have exclusive access to the data for 
12 months after the primary data are published. Anonymised 
datasets that do not contain any participant identifiers or locator 
information will be made available for data sharing in order to 
maintain participant confidentiality.
External users of the data (i.e. outside of the research group) 
will be bound by data sharing agreements in accordance with 
MRC guidelines.
Dissemination and publication policy
A dedicated study-specific website (www.wantaim.org) will 
be used to disseminate progress updates to trial participants, 
stakeholders and partners. Updates may be provided as open 
access format reports and slide presentations; video updates 
from the field, including site visits and interviews with 
in-country policy makers; and interactive webinars (e.g. on trial 
rationale, progress and anticipated impact delivered by senior 
scientists).
Key stakeholders at national, provincial, district and health 
facility level will be provided with updates via periodic news-
letters, technical reports and presentations provided by the 
in-country research team and investigators e.g. hospital grand 
round meetings; provincial health authority stakeholder meet-
ings; meetings of the PNG Obstetrics and Gynaecology Society; 
National Department of Health Technical Advisory Committees 
and Working Groups. 
A National Policy Forum will be conducted on completion of 
the trial to enable senior health care managers, policy makers 
and development partners to engage with the research team in 
understanding the implications of our research findings for 
future public health policy. The forum will be preceded by 
early consultation with national and provincial policy-makers 
to establish locally meaningful benchmarks for feasibility and 
cost-effectiveness, so that any impact statements presented in 
the forum can address both international norms and local priorities 
for sustainability.
A Publication Policy will be developed and provided to the 
Trial Steering Committee for endorsement prior to the start of 
trial enrolment. Authorship will follow the guidelines of the 
International Committee of Medical Journal Editors. Scientific 
manuscripts arising from the trial will be submitted to peer-
reviewed journals and published using the Creative Commons 
(CC-BY) open-access licence, wherever possible, and will be 
deposited in the PubMed Central (PMC) and European PMC 
repositories as soon as possible.
Discussion
WANTAIM is the first randomised trial to evaluate the effec-
tiveness, cost-effectiveness, acceptability and health system 
implementation requirements of point-of-care STI testing and 
treatment to improve birth outcomes in high-burden, low-income 
settings. If the intervention is proven to have an impact, and proves 
feasible, acceptable, and cost-effective for such settings, the 
trial will hasten access to these technologies, guide implementa-
tion, and could thereby improve maternal and neonatal health in 
high-burden, low-income settings worldwide.
Trial status
Trial protocol version 0.3. Recruitment started July 2017. Estimated 
time to complete recruitment is 3 years.
Trial registration
The trial is registered with the International Standard 
Randomised Controlled Trial Register (ISRCTN) number: 
ISRCTN37134032.
Data availability
Underlying data
All data underlying the results are available as part of the article 
and no additional source data are required.
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Extended data
Open Science Framework: WANTAIM Trial Papua New Guinea. 
https://doi.org/10.17605/OSF.IO/N58PD48.
The following extended data are available:
•    WANTAIM_Community-Volunteer_Flipchart_PNG-Pidgin.
pdf
•    WANTAIM PISICF_English_v0.5 (23Feb2018).pdf (Partici-
pant information sheet and informed consent form)
•    WANTAIM study brochure_English.pdf
•    WANTAIM study brochure_PNG-Pidgin.pdf
Reporting guidelines
Open Science Framework: SPIRIT checklist for “Point-of-care 
testing and treatment of sexually transmitted infections to improve 
birth outcomes in high-burden, low-income settings: Study 
protocol for a cluster randomized crossover trial (the WANTAIM 
Trial, Papua New Guinea)”. https://doi.org/10.17605/OSF.IO/
N58PD48.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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